ALLMedicine™ Myasthenia Gravis Center

Jun 24th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

Jun 24th, 2022 - This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Jun 24th, 2022 - A woman in her 90s with a background of myasthenia gravis and atrial fibrillation presented to hospital following a fall. While in the emergency department it was noted that she was in atrial fibrillation with a fast-ventricular response and as pa...

Jun 23rd, 2022 - Several patients with myasthenia gravis (MG) do not adequately respond to available drugs or exhibit poor tolerance, necessitating the need for new therapies. The paper discusses the rapidly evolving target-specific immunotherapies that promise lo...

Jun 22nd, 2022 - This study is a randomized, double-blind, placebo-controlled study, to be conducted at 6 study sites. Approximately 64 subjects will be enrolled. Patients with MG who are positive for anti-AChR antibodies will be enrolled. Patients who do not have...

Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

Nov 10th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

Jul 1st, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

Jun 24th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

Jun 24th, 2022 - This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Jun 22nd, 2022 - This study is a randomized, double-blind, placebo-controlled study, to be conducted at 6 study sites. Approximately 64 subjects will be enrolled. Patients with MG who are positive for anti-AChR antibodies will be enrolled. Patients who do not have...

Jun 21st, 2022 - The purpose of the study is to determine the effect acupuncture treatment on individuals with a diagnosis of Myasthenia Gravis (MG). A total of 20 people with MG will be enrolled in this study to receive acupuncture treatment 2 times a week for 12...

Jun 21st, 2022 - The duration of the DB period will be 26 weeks. The OLE is up to 104 weeks. The duration of the whole study DB+OLE is 130 weeks.

May 16th, 2022 - Two investigational medications are safe and effective for the treatment of generalized myasthenia gravis (gMG), new research shows. The phase 3 studies showed both zilucoplan and rozanolixizumab improve gMG-specific outcomes compared with placebo...

Apr 29th, 2022 - Note that some links may require registration or subscription. CDC confirmed the first human case of the H5N1 bird flu in the U.S., in a Colorado man with direct exposure to birds. Oklahoma Gov. Kevin Stitt (R) is expected to sign a "Texas-style" ...

Mar 15th, 2022 - Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG ca...

Mar 15th, 2022 - Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG ca...

Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...